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Chronic graft-versus-host disease (cGVHD) is a signiﬁcant roadblock to long-termhematopoietic stemcell (HSC)
transplantation success. Effective treatments for cGVHD have been difﬁcult to develop, in part because of
a paucity of animal models that recapitulate the multiorgan pathologies observed in clinical cGVHD. Here we
present an analysis of the pathology that occurs in immunodeﬁcientmice engraftedwith human fetal HSCs and
implantedwith fragments of human fetal thymus and liver. Starting at time points generally later than 100 days
post-transplantation, the mice developed signs of illness, including multiorgan cellular inﬁltrates containing
human T cells, B cells, and macrophages; ﬁbrosis in sites such as lungs and liver; and thickened skin with
alopecia. Experimental manipulations that delayed or reduced the efﬁciency of the HSC engraftment did not
affect the timing or progression of disease manifestations, suggesting that pathology in this model is driven
more by factors associated with the engrafted human thymic organoid. Disease progression was typically
accompanied byextensiveﬁbrosis and degradation of the thymic organoid, and therewas an inverse correlation
of disease severity with the frequency of FoxP3þ thymocytes. Hence, the human thymic tissuemay contribute T
cells with pathogenic potential, but the generation of regulatory T cells in the thymic organoid may help to
control these cells before pathology resembling cGVHD eventually develops. This model thus provides a new
system to investigate disease pathophysiology relating to human thymic events and to evaluate treatment
strategies to combat multiorgan ﬁbrotic pathology produced by human immune cells.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION sufﬁciently distinct pathophysiologies that they can be
Graft-versus-host disease (GVHD) is the major clinical
complication of hematopoietic stem cell (HSC) trans-
plantation therapies that are used to treat high-risk hema-
tological malignancies. Because GVHD is associated with
signiﬁcant rates of morbidity and mortality, it is also the
major factor preventing the wider application of HSC trans-
plantation to patients with other types of malignancies. Two
types of GVHD can develop after HSC transplantation,
termed acute (aGVHD) and chronic (cGVHD) [1]. The 2 forms
of GVHD typically produce pathology in many of the same
tissues, including skin, lung, liver, and eye, and until recently
were differentiated mainly by their time of onset (<100 days
after transplantation for aGVHD versus longer for cGVHD).
However, it is now clear that aGVHD and cGVHD involveedgments on page 1321.
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13.06.007distinguished by their clinical presentation: aGVHD is char-
acterized by inﬂammatory processes that include TH1 cyto-
kine production, cytopathic T cell activation, and necrotic
damage to target organs, whereas cGVHD appears to bemore
similar to autoimmune vascular diseases and involves
inﬂammation that leads to ﬁbrotic pathology [1-3]. The
development of improved therapeutic strategies is thus
likely to require experimental systems that accurately model
the distinct clinical manifestations of GVHD.
It is known that aGVHD is mainly due to the transfer of
mature T cells from the donor that are not tolerized to the
host’s antigenic environment, because it is prevented by
complete removal of donor T cells from the graft [1]. In
contrast, cGVHD is thought to be caused by donor cells that
develop de novo within the host from the transplanted HSCs
[3]. Cells implicated in cGVHD include T lymphocytes, B
lymphocytes, and macrophages; however, the relative
contributions of these cell types remain poorly understood.
Murine transplantation models have demonstrated that
pathology resembling cGVHD can arise through an MHC
class II mismatch protocol that leads to B cell overproductionTransplantation.
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bility mismatch protocol that results in ﬁbrosis associated
with alternatively activated macrophages [7], or through
a protocol that interfereswith the negative selection of Tcells
by MHC class IIeexpressing dendritic cells in the thymus [8].
In each of these approaches, donor T cells play a central role
in disease pathogenesis, but their cellular interactions
leading to pathology probably differ markedly. Moreover,
although experimental model systems such as these have
provided important insights into mechanisms that can lead
to cGVHD, the degree to which these systems recapitulate
the cGVHD that occurs in humans after HSC transplantation
remains a signiﬁcant concern.
Recently, it has been shown that highly immune-deﬁcient
mice that are transplanted with fragments of human fetal
thymus and liver along with autologous human fetal HSCs
manifest symptoms of GVHD at time points typically
>100 days post-transplantation [9]. Thus, this type of model
recapitulates a common feature of clinical cGVHD in humans.
However, the type of GVHD pathology that occurs in this
engraftment model is not yet well characterized. Because the
engrafted human Tcells in this model mainly seem tomature
within a human thymic organoid that develops from the
implanted thymic tissue, they may not be effectively toler-
ized to the xenogeneic environments encountered in the
murine host’s tissues. The resulting lack of peripheral toler-
ance might be expected to lead to aGVHD-like pathology. On
the other hand, because there is little or no cotransfer of
mature T cells along with the graft and the human T cells
develop from human precursor populations within the
murine host, this model recapitulates human transplantation
conditions associated with cGVHD and not aGVHD. Here, we
have undertaken an analysis designed to compare the nature
of the GVHD pathology that occurs in immunodeﬁcient mice
after engraftment of human fetal HSCs, liver, and thymus,
with that occurring after transfer of adult human peripheral
blood mononuclear cells (PBMCs) containing mature T cells,
a protocol that is known to lead to a rapid-onset xenogeneic
GVHD response bearing similarity to aGVHD.METHODS
Generation of Engrafted Mice
All research reported here was performed in accordance with protocols
approved by the University of Wisconsin’s Institutional Animal Care and Use
Committee (IACUC) and Institutional Review Board (IRB). NOD.Cg-Prkdcscid
IL2rgtm1Wjl/SzJ mice were obtained from Jackson Laboratory (stock no.
005557; Bar Harbor, ME) and bred and maintained in a speciﬁc pathogen-
free facility using sterilized cages, bedding, food, and water. Mice used for
engraftment were 6 to 8 weeks old and included both males and females.
To generate “PBMC” mice, human PBMCs were isolated from freshly
drawn blood of healthy adult donors by Ficoll-Paque density gradient
centrifugation (GE Healthcare Life Sciences). Puriﬁed PBMCs (1  107 per
mouse) were injected intravenously using an ocular injection site. For the
“HSC-L-T” engraftment protocol, the mice were conditioned with sublethal
(2 Gy) whole body irradiation before introduction of human tissues, unless
noted otherwise. Human fetal thymus and autologous liver tissues of 14 to
20 weeks of gestational age were obtained from cadaverous sources and
processed and stored in X-vivo 15 serum-free culture medium (Lonza
Biosciences, Allendale, New Jersey). Thymus and liver tissues were cut into
fragments (each approximately 1 mm3), and 1 fragment each of thymus and
of liver tissue were surgically implanted next to each other under the
capsule of the left kidney. Immediately after this surgery, the mice were
given an intravenous (ocular) injection of puriﬁed human CD34þ HSCs (1 to
4  105 cells per mouse, unless otherwise noted) that were obtained from
the same fetal liver tissue used for surgical engraftment.
HSCs were prepared by gently disrupting the liver tissue by cutting it
into small pieces and repeatedly pipetting up and down and then ﬁltering
the resulting cell suspension through a 70-mm mesh and purifying the
mononuclear cells by Ficoll-Paque (GE Healthsciences) density gradient
separation. CD34þ cells were then puriﬁed by magnetic sorting using anti-CD34 microbeads (Miltenyi Biotec, Auburn, CA). The purity of the injected
CD34þ cells was determined by ﬂow cytometric analysis to typically be at
least 80% to 90%, with less than 0.5% contamination of CD3þ cells. The
drinking water for the mice was supplemented with 0.17 to 0.25 mg/mL
Enroﬂoxacin (Bayer Healthcare, Leverkusen, Germany) for 14 days after
surgery to prevent infections.
Flow Cytometry
Successful engraftment of human cells in the mice was conﬁrmed by
ﬂow cytometric analysis of peripheral blood samples. Antibodies used to
speciﬁcally detect human cells were as follows: pan CD45 (clone HI30), CD4
(clone RPA-T4 or OKT4), CD14 (clone M5E2), CD19 (clone HIB19), and CD3
(clone SPVT-3b). Negative control antibodies used were clone P3 (IgG1) and
clone UPC10 (IgG2a). We conﬁrmed that none of these antibodies showed
signiﬁcant staining of murine cells from unengraftedmice (data not shown).
For ﬂow cytometric analysis, blood samples were collected into heparinized
tubes. The samples were then subjected to ACK lysis to remove red blood
cells, blocked with human serum, and stained using 10 mg/mL of each ﬂu-
orescently labeled antibody in a PBS buffer containing 1 mg/mL BSA. The
samples were analyzed using a ﬂow cytometer (model LSRII; Becton Dick-
inson, Franklin Lakes, New Jersey), and the data were processed using
Flowjo software (Tree Star, Inc.).
Symptom Tracking
Engraftedmicewereweighed and evaluated for evidence of symptoms 2
to 3 times each week. Symptom scores were determined blindly, without
access to engraftment protocol or prior scoring history. The categories used
for scoring were hunching and lethargy, squinting, and alopecia. Alopecia
was scored separately for the back, forehead, abdomen, face and nose, and
around the eyes. The average of the individual scores for these siteswas then
taken to generate the total alopecia score. A scale of 0 to 3 was used for each
symptom category, according to the following benchmarks:
 Hunching and lethargy: 0 ¼mouse runs around during weighing and is
able toextendbody fully;1¼mouseshowslittlemovement incontainer
during weighing; 2 ¼ mouse remains in a curled position during
weighing; 3¼ spine of mouse is curved and not able to fully straighten
 Squinting: 0 ¼ eyes appear round and blinking does not occur more
frequently than once every 10 seconds; 1 ¼ eyes are able to open fully
but blinking in 1 or both eyes occurs more frequently than once per
10 seconds; 2¼ eyes never appear to open all theway; 3¼ eyes remain
shut during weighing or eyes are partially open and show evidence of
crustiness around eyelids or whiteness is visible on cornea
 Alopecia: 0 ¼ fur appears of normal density (although some rufﬂing
may be visible); 1 ¼ some evidence of fur thinning; 2 ¼ patches of
skin are visible; 3¼ skin is exposed and shows evidence of rawness or
bleeding
Composite symptom scores were determined by the taking the sum of
the squinting, hunching, and average alopecia scores for each mouse. Mice
were declared moribund when they were found to have undergone at least
15% loss of body weight or their disease manifestations interfered with their
ability to eat or drink as determined by veterinarians blinded to experi-
mental group. Moribund mice were killed by CO2 inhalation according to
IACUC guidelines.
Histology
Tissues were ﬁxed in 10% buffered formalin and embedded in parafﬁn
before sectioning. Sections were deparafﬁnized and processed for H & E
staining or immunohistochemistry. Immunohistochemistry was performed
using antibodies against the following human antigens: CD3 or CD45 (Bio-
care Medical, Concord, CA), CD68 (DAKO, Carpinteria, CA), or CD20 (BD-
Pharmingen, Franklin Lakes, NJ). Antigen retrieval was performed using
rodent decloaker (Biocare Medical). Antibody labeling was detected and
visualized using a horseradish peroxidaseepolymer kit with dia-
minobenzidine development (Biocare Medical). Collagen deposition in
tissue sections was visualized using a Gomori 1-step aniline blue trichrome
kit (Newcomer Supply, Inc., Middleton, WI) according to the manufacturer’s
protocol. Histochemically stained tissue sections were analyzed by light
microscopy using a Nikon Eclipse microscope (Melville, NY), and color
photographic images were acquired using a Spot Insight camera.
Liver Enzyme Quantiﬁcation
Blood samples collected into heparinized tubes were centrifuged to
pellet the cells, and plasmawas withdrawn and stored frozen at20C until
analysis. Plasma samples were analyzed in parallel for aspartate trans-
aminase (AST) and alanine transaminase (ALT) enzyme activity levels using
slides (Vitros Chemistry Products) on a Vitros 5,1 FS Chemistry System
automated analyzer (Ortho Clinical Diagnostics, Rochester, NY).
%
 W
e
ig
h
t
 c
h
a
n
g
e
Weeks postengraftment
HSC-L-T
PBMC
Engraftment
Batch:
0 5 10 15 20 25 30
0
20
40
60
80
100
#1
#2
#3
#4
#5
#6
Weeks postengraftment
%
 
H
e
a
lt
h
y
 
(
S
S
<
2
)
0 2 4 6 8 10 12 14 16 18 20 22 24 26
-30
-20
-10
0
10
20
0 2 4 6 8 10 12 14 16 18 20 22 24 26
0
2
4
6
8
C
o
m
p
o
s
it
e
s
y
m
p
t
o
m
 s
c
o
r
e
HSC-L-T
PBMC
Weeks postengraftment
Figure 1. Timing and progression of GVHD in transplanted mice. (A) Plot
showing timing of disease onset (deﬁned as a composite symptom score of 2.0
or greater) in 6 different engraftment batches of HSC-L-T mice. The numbers of
mice included in each batch are as follows: 8 in batch 1, 9 in batch 2, 13 in
batch 3, 12 in batch 4 (3 censored), 9 in batch 5, 9 in batch 6. The survival
curves for the batches were signiﬁcantly different (P < .0001, using a log-rank
Mantel-Cox test), and median times at onset ranged from 11.0 to 22.3 weeks
postengraftment. (B and C) Plots showing progression of weight change and of
visible pathology in 9 individual PBMC mice from 4 different engraftment
batches (gray symbols) and in 10 individual HSC-L-T mice from batch 3 (black
symbols). The plot in B shows the percent weight change over time of each
mouse compared with its starting measurement, and the plots in C show the
results over time from evaluation of each mouse using a blinded scoring
system that generated a composite symptom score on a scale of 0 to 9.
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Plasma samples were analyzed for levels of human Igk light chain using
a sandwich ELISA. Brieﬂy, high-proteinebinding microtiter plates were
coated with a capture mAb speciﬁc for human Igk light chain (clone MHK-
49; Biolegend, San Diego, CA) at a concentration of 2 mg/mL and then
blocked with 10 mg/mL BSA in PBS. Samples included plasma from
engrafted mice or human serum as a positive control and were diluted
before analysis in medium containing 10% bovine calf serum. Detection was
accomplished using a biotinylated version of the same anti-Igk mAb (Bio-
legend), followed by streptavidinehorseradish peroxidase and visualization
using a TMB substrate.
RESULTS
Immunodeﬁcient NOD mice bearing the Prkdcscid
mutation and having a genetic deletion of the common g
chain of the IL-2 receptor (hereafter called “NSG” mice)
were used for engraftment. Two different engraftment
models were used. In the ﬁrst, the mice were subjected tosublethal total body irradiation, and then fragments of
human fetal liver and thymus tissue were surgically
implanted under the kidney capsule and autologous human
CD34þ HSCs were intravenously injected (“HSC-L-T” mice).
HSC-L-T mice were generated in batches of 8 to 14 mice
engrafted with the same set of autologous human tissues. In
the secondmodel, the mice were not irradiated (because we
observed in preliminary experiments that total body irra-
diation of these mice typically led to mortality within
2 weeks after transplantation) and were simply intrave-
nously injected with puriﬁed adult human PBMCs (here-
after called “PBMC” mice). For mice engrafted with PBMCs,
batches of 3 to 6 mice were injected with cells from a single
human donor.
To assess disease onset and progression, the mice were
regularly weighed and scored for visible signs of pathology
(ie, hunching and lethargy, eye irritation, alopecia). There
was no evidence of GVHD in any of the HSC-L-T mice
generated in this study for at least 10 weeks, and disease
onset typically did not occur until >100 days post-
transplantation (Figure 1A). However, the timing of GVHD
onset differed signiﬁcantly (P < .0001) among the 6 batches
of HSC-L-T mice that we assessed in this analysis, with the
median times varying from 11.0 to 22.3 weeks after trans-
plantation (Figure 1A). Near the time of disease onset, the
HSC-L-T mice sometimes showed a modest decline in body
weight (typically 10%), but weight loss did not become
more severe until 8 to 12 weeks later (Figure 1B). They also
developed conditions such as blinking or squinting, alopecia,
and hunched posture that gradually progressed in severity
(Figure 1C). Histological analyses conﬁrmed the presence of
inﬂammatory inﬁltrates in the eyelids, conjunctiva, and
lacrimal glands of mice that showed signs of eye irritation
(Table 1), and immunohistochemical analysis demonstrated
that the inﬁltrating cells were largely composed of human T
cells (Figure 2B). Similarly, alopecia was associated with
marked inﬁltration of human Tcells into the base and shaft of
hair follicles (Figure 3B,C).
The PBMC-engrafted mice showed a different pattern of
GVHD manifestations. Disease onset occurred within
4 weeks post-transplantation in these mice (Figure 1B and
C). Although they typically gainedweight in the ﬁrst 2 weeks,
they then generally began to lose weight, becoming mori-
bund within about 6 weeks post-transplantation (Figure 1B).
The signs of GVHD observed in these mice were mainly
hunching, lethargy, and eye irritation, with little or no
alopecia (Figures 2 and 3). Consistent with the low incidence
of alopecia, histological and immunohistochemical analyses
of the PBMC mice demonstrated that although there was
extensive inﬁltration of the skin by human cells, the inﬁl-
tration tended to be more conﬁned to dermal rather than
epidermal layers, and there was much less evidence of
human T cells within hair follicles (Figure 3B and C).
Histopathology of Internal Organs
To further evaluate the GVHD pathology arising in the 2
types of engrafted mice, we performed histological and
immunohistochemical analyses of a series of tissues.
Whereas there was little evidence of inﬂammation or
pathology in nonsymptomatic HSC-L-T mice, there was
substantial cellular inﬁltration and other signs of pathology
in most tissues and organs from both PBMC mice and
symptomatic HSC-L-T mice (Table 1). However, there were
noticeable differences in the nature of the pathology in HSC-
L-T mice compared with PBMC mice.
Table 1
Summary of Results from Necropsy and Histological Analyses of Tissues from Engrafted Mice
Nonsymptomatic
HSC-L-T
Symptomatic HSC-L-T Symptomatic PBMC
Mouse
No. 81
Mouse
No. 86
Mouse
No. 63
Mouse
No. 83
Mouse
No. 60
Mouse
No. 57
Mouse
No. 1
Mouse
No. 3
Mouse
No. 5
Mouse
No. 6
Sex F M M F M M F F M M
Irradiated Yes Yes Yes Yes Yes Yes No No No No
Days postengraftment at time of analysis 120 120 134 155 128 142 42 35 35 35
Skin
Epidermal thickening and hyperkeratosis e e þ þ þ þ e e e e
Epidermal or subepidermal cellular
inﬁltration
e e þ þ þ þ þ e e e
Dermal cellular inﬁltration e e e e þ þ þ þ
Lung
Peribronchiolar and perivascular inﬁltration e þ þ þ þ þ þ þ þ þ
Alveolar interstitial epithelial hyperplasia e e þ þ þ þ þ þ þ þ
Type II pneumocytes e e e e e e e þ þ þ
Liver
Portal triad inﬁltration þ þ þ þ þ þ þ þ þ þ
Parenchymal inﬁltration e e þ þ þ þ þ þ þ þ
Macrophage-lymphocyte clusters e þ þ þ þ e e e e
Bile duct effacement or reduplication e e e þ e þ e e e e
Other
Eye: Conjunctival or lacrimal gland
inﬁltration
e e þ þ þ þ e þ þ þ
Nose: Nasal passage, sinus, or olfactory lobe
inﬁltration
þ e þ þ þ þ þ þ þ þ
Ear: Inner or outer ear canal inﬁltration þ þ e þ þ þ þ þ þ þ
Tongue: Submucosal inﬁltration e e e e e e þ þ þ þ
Salivary gland: Atrophy of the submandibular
gland
e e e e e þ þ þ þ e
Brain: Meningeal inﬁltration e e e e e e e þ þ þ
Gastrointestinal tract: Diarrhea e e e e e e e e e e
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bronchiolar and perivascular cellular inﬁltration with less
evidence of inﬂammation in the smaller airways and alveoli,
whereas cellular inﬁltration was typically extensively
present in both peribronchiolar areas and the parenchymal
spaces around the alveoli in PBMC mice (Figure 4A). The
makeup of the cellular inﬁltrate in the lungs of HSC-L-T mice
consisted of a mixture of human T cells, B cells, and macro-
phages, whereas in PBMC mice the cellular inﬁltrate was
dominated by human T cells with few B cells and little or
no evidence of macrophages (Figure 4B). Additionally,
immunohistochemical staining for collagen showed areas
of increased collagen deposition, particularly around the
bronchioles, in symptomatic compared with non-
symptomatic HSC-L-T mice (Figure 4C). In contrast, despite
the widespread inﬂammation in the lungs of PBMCmice, theFigure 2. Evaluation of eye irritation. (A) Plot showing the results of a blinded analysis
T mice, using a scale of 0 (no pathology) to 3 (most severe pathology). (B) Immunoh
staining). The tissue was from a symptomatic HSC-L-T mouse at 172 days post-trans
inﬂammatory inﬁltrates were observed by histological analysis of H & Eestained tissu
and 3 additional PBMC mice.comparatively modest levels of collagen staining suggested
little ﬁbrosis (Figure 4C). However, histological analysis
suggested proliferation of type II pneumocytes in the alveoli
of the PBMC mice, consistent with alveolar insult (Table 1).
The livers of symptomatic HSC-L-T mice and PBMC mice
clearly showed inﬂammatory inﬁltrates of human leukocytes
that were not present in nonsymptomatic engrafted mice
(Figure 5A). In both types of symptomatic mice, the cellular
inﬁltrates were present around portal triads and extended
into the parenchyma (Figure 5A); however, there were
differences in the cellular composition of the inﬁltrates. In
PBMCmice, they were composed mainly of T cells with some
B cells but little or no evidence of monocytic cells (Figure 5B).
In contrast, in HSC-L-T mice, they prominently included
clusters of epithelioid-like macrophages surrounded by T
lymphocytes and a few B cells (Figure 5B). HSC-L-T miceof eye condition over time in 9 individual PBMC mice and 10 individual HSC-L-
istochemical analysis of eyelid tissue for cells expressing human CD3 (brown
plantation and was photographed at 20 magniﬁcation. Similar mononuclear
e (eyelids, conjunctiva, and/or lacrimal glands) from 5 additional HSC-L-T mice
Figure 3. Evaluation of alopecia and skin pathology. (A) Plot showing the results of a blinded analysis of alopecia over time in 9 individual PBMC mice and 10
individual HSC-L-T mice, using a scale of 0 (no pathology) to 3 (most severe pathology). (B and C) Immunohistochemical analyses of skin sections taken from a PBMC
mouse at 35 days post-transplantation (left plots) and a symptomatic HSC-L-T mouse at 172 days post-transplantation (right plots) for cells expressing human CD45
(B) or human CD3 (C). Evidence of similar cellular inﬁltration and localization was observed by histological analysis of H & Eestained skin sections from 7 additional
HSC-L-T mice and 3 additional PBMC mice.
J.L. Lockridge et al. / Biol Blood Marrow Transplant 19 (2013) 1310e13221314sometimes also showed evidence of bile duct effacement,
whereas this was not observed in PBMC mice (Table 1).
Additionally, collagen staining in the liver was dramatically
increased in symptomatic HSC-L-T mice compared with
nonsymptomatic mice (Figure 5C), suggesting a highly
ﬁbrotic pathology. Symptomatic PBMC mice showed less
collagen staining in the liver than symptomatic HSC-L-T mice
(Figure 5C), suggesting the inﬂammatory pathology in these
mice was not as highly ﬁbrotic.
Analysis of the levels of transaminase enzyme activity in
blood plasma samples from the engrafted mice providedfurther evidence of differences in liver pathology. We tested
for enzyme activity levels of AST, which is released from liver
as well as other tissues upon cellular damage, and also of ALT,
which is produced only by hepatocytes and thus more
speciﬁcally indicates damage to the liver. Compared with
nonsymptomatic HSC-L-T mice, plasma samples from
symptomatic HSC-L-T mice had slightly elevated activity
levels of AST and ALT (Figure 6), although the differences
were not statistically signiﬁcant. In contrast, plasma samples
from PBMC mice had approximately 5-fold greater AST
and 10-fold greater ALT enzyme activity levels than the
Figure 4. Lung inﬂammation. (A) Lung tissue sections taken from a PBMC mouse at 35 days post-transplantation, a symptomatic HSC-L-T mouse at 142 days post-
transplantation, and a nonsymptomatic HSC-L-T mouse at 120 days post-transplantation were ﬁxed and stained for cells expressing the human CD45 marker
(visualized by brown coloration) to detect the presence of human leukocytes. (B) Immunohistochemical staining of serial sections of lung tissue from the same mice
shown in A for cells expressing the human CD3, CD20, or CD68 markers (all visualized by brown coloration) to detect T cells, B cells, or macrophages, respectively. (C)
Gomori trichrome staining of lung tissue sections from the same mice to detect collagen depositions. Bright blue color indicates collagen ﬁbers; red or pink
coloration indicates keratin or muscle ﬁbers or cytoplasm of cells. Photographs in all panels were taken at 10  magniﬁcation. Similar immunohistochemical results
were observed for 4 HSC-L-T mice, and evidence of similar cellular inﬁltration and localization was observed by histological analysis of H & Eestained skin sections
from 7 additional HSC-L-T mice and 3 additional PBMC mice.
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Figure 5. Liver inﬂammation. (A) Liver tissue sections taken from a PBMC mouse at 35 days post-transplantation, a symptomatic HSC-L-T mouse at 134 days post-
transplantation, and a non symptomatic HSC-L-T mouse at 228 days post-transplantation were ﬁxed and stained for cells expressing the human CD45 marker (brown
color). Photographs were taken at 20magniﬁcation. (B) Sections of liver tissue from the mice shown in A were stained for cells expressing the human CD3, CD20, or
CD68 markers (brown color). Images are shown at 40magniﬁcation. (C) Gomori trichrome staining showing collagen deposition (blue color) in liver tissue sections
from the indicated mice. Images are shown at 40 magniﬁcation. Similar immunohistochemical results were observed for 4 HSC-L-T mice, and evidence of
similar cellular inﬁltration and localization was observed by histological analysis of H & Eestained skin sections from 7 additional HSC-L-T mice and 3 additional
PBMC mice.
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Figure 6. Transaminase enzyme activity in the plasma of transplanted mice.
Plasma samples from the indicated types of engrafted mice were tested for
activity levels of the transaminase enzymes AST (open circles) and ALT (ﬁlled
triangles). Each symbol represents the result from an individual engrafted
mouse. Nonsymptomatic HSC-L-T mice were 15 weeks postengraftment at the
time of analysis; symptomatic HSC-L-T mice were 19 to 40 weeks post-
engraftment; PBMC mice were 3 to 7 weeks postengraftment. AST and ALT
enzyme activity values were not signiﬁcantly different for nonsymptomatic
and symptomatic HSC-L-T mice, but were signiﬁcantly different for symp-
tomatic HSC-L-T mice versus PBMC mice (P < .001 for both) using a 2-tailed
Mann-Whitney test.
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that appeared to be statistically signiﬁcant in both cases
(P < .001, using a 2-tailed Mann-Whitney test). These results
thus support the presence of a more acute hepatitis in the
PBMC mice, whereas the lower serum transaminase enzyme
activity and greater evidence of ﬁbrosis in the symptomatic
HSC-L-T mice are more consistent with what is observed
clinically in cGVHD patients [10].
Both types of mice frequently showed histological
evidence of inﬂammatory cellular inﬁltration in the nasal
passages, including sinuses and olfactory lobes, and in the
inner and outer ear canals (Table 1). Occasionally, inﬂam-
matory inﬁltrates were also observed in teeth, genitalia, and
stomach, although neither the HSC-L-T nor the PBMC mice
showed evidence of diarrhea (Table 1). Notably, PBMC mice
usually also hadmarked cellular inﬁltrates in the submucosal
layers of the tongue, atrophy of the submandibular salivary
glands, and substantial evidence of meningeal inﬁltration in
the brain, whereas these sites rarely appeared to be affected
in the HSC-L-T mice (Table 1). Thus, although both types of
mice showed histopathology at multiple tissue and organ
sites, the affected tissues were somewhat more restricted in
the HSC-L-T mice as compared with the PBMC mice, and the
nature of the inﬂammatory inﬁltrates differed, with more
evidence of macrophages and ﬁbrotic processes in the HSC-
L-T mice.
Role of HSC versus Thymic Organoid Engraftment
Development of GVHD symptoms has not been reported
in immunodeﬁcient mice that receive human HSCs without
concurrent implantation of thymic and liver tissue, and
hence it seems likely that the GVHD that develops in the
HSC-L-T model requires the presence of the human thymic
organoid, which promotes T cell engraftment [11]. Although
it is clear that long-term engraftment by human T cells
requires both the sustained survival of the thymic organoid
and bone marrow engraftment of human HSCs [12], the
relative importance of the thymic tissue versus the HSCs to
the development of GVHD is not clear. To investigate this, wegenerated HSC-L-T mice that were all implanted with similar
sizes of human thymic and liver fragments but were
administered different doses of HSCs. Mice that received the
lowest dose of HSCs (1  104 cells per mouse) showed
delayed emergence of human leukocytes in the periphery
but eventually developed levels of engraftment similar to
mice that received higher doses of HSCs (1  105 or 2  105
cells per mouse) (Figure 7A). In the mice that received the
lowest HSC dose, the human leukocyte population was
initially highly skewed toward T cells with only very low
frequencies of B cells, but over time the lymphocyte
proportions became similar to those of mice that were
administered higher doses of HSCs (Figure 7A). Remarkably,
the reduced dose of HSCs had no impact on the time of GVHD
symptom onset, rate of symptom progression, or degree of
symptom severity (Figure 7B). These results suggested that
the development of GVHD in this model is not highly
dependent on the rate of HSC engraftment.
To further investigate, we compared mice that were
irradiated before engraftment with mice that had not been
irradiated. Irradiation not only suppresses host immune
responses that might attack the engrafted cells, it also
directly facilitates engraftment of HSCs by making space in
the bone marrow. Therefore, non-irradiated mice should
have diminished or delayed HSC engraftment, but there
should be little or no impact on the engraftment of the
thymic organoid. Interestingly, there was no difference
between irradiated and non-irradiated mice in the timing of
GVHD onset, and the non-irradiated mice showed similarly
widespread histopathology as the irradiated mice (Figure 7C
and Table 2). The non-irradiated and irradiated mice had
comparable levels of T cells, but the irradiated mice had
much lower levels of circulating B cells (mean of .2% of the
PBMC for irradiated versus 9.4% for non-irradiated)
(Figure 7D). Notably, despite the very low B cell frequencies
in non-irradiated mice, we found that these mice had clearly
detectable human immunoglobulin in their plasma and that
their levels of immunoglobulin increased to nearly the same
levels as irradiated mice at late time points after trans-
plantation (Figure 7E). Thus, although efﬁcient B cell recon-
stitution does not seem to be required for the development
of GVHD in this model, there may nevertheless be a role for B
cell activation during disease progression. However, because
the efﬁciency of HSC engraftment and B cell reconstitution
did not produce a marked effect on GVHD disease onset,
these results directed our attention to the human thymic
organoid.
Thymic Organoid Histopathology
Histological analyses of the engrafted kidneys of HSC-L-T
mice with moderate or severe GVHD symptoms consistently
revealed extensive ﬁbrosis at the border between the kidney
and the thymic organoid and structural degradation of the
organoid itself, whereas the engrafted kidneys and thymic
organoids of nonsymptomatic mice typically appeared to be
healthy (Figure 8A). We also found that cells staining
strongly for the Forkhead box P3 transcription factor (FoxP3),
a marker of regulatory T cells (Tregs), were present in the
medullary areas of thymic organoids from nonsymptomatic
HSC-L-T mice (Figure 8B, left). In contrast, there was little
evidence of cells staining strongly for FoxP3 in thymic
organoids from mice with severe GVHD symptoms
(Figure 8B, right). A blinded quantitation of the number of
FoxP3þ cells per ﬁeld in a series of slides from mice with
varying GVHD symptom scores revealed an inverse
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Figure 7. The impact of modulating HSC engraftment on the development of GVHD. (A) An engraftment batch of HSC-L-T mice was divided into 3 groups (4 to 6 mice
in each) that were all implanted with similar-sized fragments of human fetal thymus and liver tissue, and each group was administered a different dose of puriﬁed
human CD34þ HSCs. The plot on the left shows the mean frequencies of cells in the blood expressing the human CD45 marker, as determined by ﬂow cytometric
analysis. Plots on the right show the mean percentages of the human CD45þ cells that expressed CD3 (T cells), CD19 (B cells), or CD14 (monocytes). Error bars show
the standard deviations of the means. (B) Plot showing composite GVHD symptom score over time for each group of mice shown in A as determined by a blinded
analysis. (C) Mice were either subjected to sublethal irradiation or not irradiated before implantation of human fetal thymus and liver fragments and administration
of puriﬁed human CD34þ HSCs (1  105 per mouse). The plot shows the time of GVHD symptom onset for individual mice in each group. The 2 groups were not
signiﬁcantly different. (D) Frequencies of cells expressing human CD3 (T cells) or human CD19 (B cells) in the peripheral blood of individual mice in the 2 groups at
15 weeks postengraftment. T cell frequencies were not signiﬁcantly different for the 2 groups, but the B cell frequencies showed a signiﬁcant difference (P ¼ .0022),
using a 2-tailed Mann-Whitney test. (E) The amount of circulating human Igk light chain was estimated by using a sandwich ELISA to test plasma samples drawn from
irradiated and non-irradiated mice at the indicated times after engraftment. The plot shows the mean optical density values obtained from samples from 4 irradiated
and 3 non-irradiated mice, with error bars indicating the standard deviations of the means.
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(Figure 8C). Together, these observations further underscore
an association between the biological properties of the
engrafted human thymic organoid and the development of
GVHD pathology in the HSC-L-T model.
DISCUSSION
The results presented here demonstrate for the ﬁrst time
that immune-deﬁcient mice administered human fetal HSCs
and concurrently implanted with fragments of human fetal
thymus and liver go on to develop pathologies that resemble
cGVHD. Speciﬁcally, we show that the HSC-L-T mouse
engraftment model recapitulates a number of features of
cGVHD observed in human HSC transplantation patients.First, GVHD symptoms did not typically appear in HSC-L-T
mice until >100 days post-transplantation, similar to the
timing at which cGVHD tends to occur in human patients [2].
Second, human patients with cGVHD frequently have
alopecia (hair loss) and scleroderma-like pathology, a condi-
tion characterized by chronic inﬂammation and ﬁbrosis in
which the skin becomes thickened with reduced elasticity
[13]. In the HSC-L-Tmousemodel, the skin became thickened
and tight with restricted ﬂexibility, there was often signiﬁ-
cant alopecia, and there was evidence of extensive inﬁltra-
tion of the epidermal layers by human hematopoietic cell
types. Third, lung involvement in human patients with
cGVHD generally manifests as constricted breathing result-
ing from inﬂammation around the bronchioles and ﬁbrosis
Table 2
Summary of Histopathology Observed in Irradiated versus Non-Irradiated HSC-L-T Mice
Irradiated HSC-L-T Non-Irradiated HSC-L-T
Mouse
No. 63
Mouse
No. 83
Mouse
No. 60
Mouse
No. 57
Mouse
No. 64
Mouse
No. 67
Mouse
No. 69
Mouse
No. 71
Sex M F M M M M M M
Irradiated Yes Yes Yes Yes No No No No
Days postengraftment at time of analysis 134 155 128 142 142 128 209 217
Skin
Epidermal thickening and hyperkeratosis þ þ þ þ þ þ þ þ
Epidermal or subepidermal cellular inﬁltration þ þ þ þ þ þ þ
Dermal cellular inﬁltration e þ e e þ e þ e
Lung
Peribronchiolar and perivascular inﬁltration þ þ þ þ þ þ þ þ
Alveolar interstitial epithelial hyperplasia þ þ þ þ þ þ þ þ
Type II pneumocytes e e e e e þ þ þ
Liver
Portal triad inﬁltration þ þ þ þ þ þ þ þ
Parenchymal inﬁltration þ þ þ þ þ þ þ þ
Macrophage-lymphocyte clusters þ þ þ þ þ þ þ þ
Bile duct effacement or reduplication e þ e þ þ þ e e
Other
Eye: Conjunctival or lacrimal gland inﬁltration þ þ þ þ þ e þ þ
Nose: Nasal passage, sinus, or olfactory lobe inﬁltration þ þ þ þ e e e e
Ear: Inner or outer ear canal inﬁltration e þ þ þ þ þ þ þ
Tongue: Submucosal inﬁltration e e e e e þ e þ
Salivary gland: Atrophy of the submandibular gland e e e þ e þ e e
Brain: Meningeal inﬁltration e e e e e e e e
Gastrointestinal tract: Diarrhea e e e e e e e e
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We found that the lungs of HSC-L-T mice showed cellular
inﬁltration mainly around the bronchioles, with less inﬁl-
tration in the parenchymal spaces around the alveoli, and
there appeared to be an excess of collagen deposited around
the bronchiolar passages. Fourth, liver pathology observed in
cGVHD patients typically entails bile duct inﬂammation,
leading to cholestasis and ﬁbrotic damage [10,15]. The livers
of symptomatic HSC-L-T mice consistently had substantial
cellular inﬁltrates around the portal triads and sometimes
showed evidence of bile duct effacement. Histological and
immunohistochemical analyses of the inﬂammatory inﬁl-
trates revealed prominent granulomatous aggregates con-
taining epithelioid-like macrophages, which are often
associated with ﬁbrosis. Moreover, histological staining for
collagen deposition suggested substantial ﬁbrosis of the liver
tissue. Analysis of plasma samples for liver transaminase
enzyme activity suggested liver damage in the HSC-L-T mice,
although not as acute as that observed in the PBMC model.
Thus, liver pathology in the HSC-L-T mice resembled that
observed in cGVHD patients in that it included substantial
ﬁbrosis and appeared to have a chronic rather than acute
inﬂammatory proﬁle. Finally, dry eye syndrome is also often
associated with cGVHD in human transplantation patients
[16]. This syndrome is caused by inﬂammation of the
conjunctiva or cornea and is often associated with impair-
ments in tear production and distribution and accompanied
by symptoms of eye irritation, itching, and sensitivity to light.
Resembling this, we noted that the HSC-L-T mice usually
developed symptoms of squinting and showed histological
and immunohistochemical evidence of immune cells inﬁl-
trating the eyelids, conjuctiva, and/or lacrimal glands. Thus,
in contrast to the GVHD that develops in NSG mice after
transplantation of adult human PBMCs, which has more
aGVHD-like characteristics, the HSC-L-T model produces
multiorgan ﬁbrotic pathologies more similar to cGVHD.
It is also interesting that the nature of the GVHD
pathology we observed in the HSC-L-T model more closelyresembles sclerodermatous cGVHD rather than the systemic
lupus erythematosuselike manifestations observed in some
murine-into-murine models of cGVHD [3]. Sclerodermatous
cGVHD pathology arises in murinemodels inwhichmature T
cells are transplanted from a minor histocompatibility
antigen mismatched donor and in models in which thymic
negative selection is impaired in the host after trans-
plantation [3]. Our observation that experimental manipu-
lations that impacted the efﬁciency of HSC engraftment had
little or no detectable effect on GVHD onset or progression
suggests that processes involving the engrafted human
thymic organoid may be the dominant drivers of pathology
in the HSC-L-T model. Consistent with this, we found that in
NSG mice that receive human HSCs alone (with no thymic
graft), there is little or no evidence of GVHD for at least
6 months after transplantation (data not shown). Thus, it
seems reasonable to speculate that the high efﬁciency and
long-lasting nature of humanTcell engraftment conferred by
the coengrafted human thymic organoid may promote the
development of GVHD in HSC-L-T mice.
Importantly, the thymic organoid in this model includes
human thymic epithelial cells as well as dendritic cells
[17,18], which are the cell types known to be responsible for
positive and negative selection of developing T cells. Thus, it
seems likely that T cells developing in the engrafted human
thymic organoid encounter human antigen-presenting
molecules upon which they may undergo positive and
negative selection. Successful positive selection of devel-
oping T cells on these antigen-presenting molecules would
facilitate their subsequent ability to interact productively
with human antigen-presenting cells that develop from the
engrafted HSCs, such as macrophages and B cells. However, if
the human thymic organoid provides an environment in
which mainly peptides of human origin are involved in
negative selection, this step might fail to remove T cells that
can recognize murine peptides. A failure to tolerize the
human T cell repertoire against murine peptides might result
in the pathogenic activation of human T cells by human
Figure 8. Integrity of the human thymic organoid after development of GVHD. (A) Gomori trichrome staining of a section of the engrafted kidney of a non-
symptomatic mouse at 120 days post-transplantation and a symptomatic mouse at 134 days post-transplantation. The collagen staining (blue color) indicates
extensive ﬁbrosis at the border between the thymic organoid and the kidney in the symptomatic mouse, but much less in the nonsymptomatic mouse. Images are
shown at 2magniﬁcation and are representative of 2 different mice each. Additional evidence of variable amounts of ﬁbrosis of the thymic organoid that seemed to
correlate with GVHD status was observed from analysis of H & E-stained tissues from 8 symptomatic and 3 nonsymptomatic HSC-L-T mice. (B) Immunohistochemical
analysis of human thymic organoid sections from a nonsymptomatic mouse at 120 days post-transplantation compared with a symptomatic mouse at 134 days post-
transplantation for cells expressing FoxP3 (brown color). Images are shown at 20 magniﬁcation. (C) Compiled results of a blinded analysis of the frequency of cells
staining positively for FoxP3 in a thymic organoid tissue section (as shown in B) in relation to the GVHD symptom score of the mouse.
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murine proteins and are thus presenting murine peptides on
their MHC molecules. It is also possible that the selection
processes in the human thymic organoid might fail to efﬁ-
ciently remove T cells that can xenogeneically cross-react on
murine antigen-presenting molecules, and that such T cells
might therefore become directly activated by host cells
encountered in the periphery. In either case, it seems plau-
sible that the similarity of this HSC-L-T model to murine
models of sclerodermatous cGVHD results from a failure to
properly tolerize the T cell repertoire during negative selec-
tion in the engrafted thymic organoid.
Consistent with observations that cGVHD in humans is
associated with impairments in thymic function [19-21], we
also noted that HSC-L-T mice with GVHD showed structural
effacement of the engrafted thymic organoid, whereas theengrafted thymic tissue appeared healthy in mice that did
not develop GVHD symptoms. Although it is not clear from
this type of observation whether thymic damage is a cause
or an effect of GVHD pathology, it is noteworthy that the
severity of GVHD symptoms in the HSC-L-T mice correlated
inversely with the frequency of FoxP3þ T cells among the
medullary thymocytes. It is thus tempting to speculate that
Tregs that are generated in the human thymic organoid may
serve to limit the pathogenic activities of other T cells in the
periphery. In this scenario, a reduction in the frequency of
Tregs that is associated with degradation of the thymic
organoid might serve to "release" pathogenic T cells in the
periphery from inhibition, leading to further GVHD
pathology. Notably, 2 studies using similar HSC-L-T models
demonstrated the suppressive functions of human Tregs in
the peripheral tissues of engrafted mice [22,23], supporting
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functioning human thymic tissue helps to prevent GVHD.
Lower levels of Tregs have also been found in HSCT patients
with severe cGVHD [24], supporting the idea that these cells
may be involved in preventing pathogenesis in clinical
settings.
In this regard, it is also worth considering the role of the
human fetal liver tissue that is implanted next to the thymic
tissue in the HSC-L-T model. Fetal liver tissue has historically
been included in most protocols that engraft human thymic
tissue into immune-deﬁcient mice [11], because it appears
to promote the engraftment and survival of the thymic
organoid. However, in addition to CD34þ HSCs, the fetal liver
tissue that we use contains mature T cells and probably also
other cell types such asmesenchymal cells thatmay inﬂuence
the development of GVHD. Indeed, although we have not
conducted a side-by-side controlled analysis, we observed
that signs of GVHD developed remarkably early (approxi-
mately 8 weeks postengraftment) in a group of 7 mice
transplanted with HSCs and thymic tissue without the fetal
liver fragment (data not shown). Thus, the fetal liver tissue
mayhelp to delay the onset of GVHD, either by prolonging the
survival of the thymic organoid and thus the thymic produc-
tion of Tregs, or by contributing other regulatory cell types.
The role of B cells in the development of GVHD in the
HSC-L-T model also remains unclear. A recent analysis in
a murine-into-murine model of allogeneic HSC trans-
plantation resulting in cGVHD, which produces multiorgan
pathologies with similarities to those seen here, suggests an
important role for B cells and alloantibody deposition, in
addition to the actions of CD4þ T cells [25]. Given that B cells
were clearly detected in inﬂammatory inﬁltrates in symp-
tomatic mice, it is reasonable to conclude they are involved
in the disease pathophysiology. However, because mice that
were not conditioned by sublethal irradiation before
engraftment showed highly impaired B cell development yet
went on to develop GVHD similarly to mice that had normal
B cell engraftment, it seems that efﬁcient B cell engraftment
is not required for GVHD onset in this model. Thus, we
conclude that B cells may contribute to disease pathology
and progression, although they may not be the most
important disease initiators. This is consistent with our
observation that even in engrafted mice that have very low
frequencies of B cells, the circulating human immunoglob-
ulin levels rise at late time points after transplantation,
suggesting progressive activation of those B cells that are
present. However, to understand the role of B cells in this
model, it will be critical to evaluate the extent to which the
secreted human immunoglobulin reacts with murine tissue
antigens.
Taken together, the results presented here demonstrate
that the HSC-L-T model provides a sophisticated experi-
mental system to investigate multiorgan ﬁbrotic pathologies
resulting from engraftment of human immune cells. It is
important to note that because of signiﬁcant divergences
between this experimental model and clinical HSC trans-
plantation protocols (eg, the cotransplantation of thymus
and liver tissue) as well as the xenogeneic nature of this
system, it is not necessarily an accurate representation of
what happens clinically in humans during cGVHD. However,
this model provides a unique opportunity to evaluate
preventative and therapeutic treatments for cGVHD in the
context of human immune reconstitution, which may be
important because human immune cells differ in multiple
ways compared with their murine counterparts.A particular strength is that due to its inclusion of human
thymic tissue, this model will allow the exploration of
methods to enhance thymopoiesis or thymic functioning and
studies aimed at dissecting how thymic events are connected
to peripheral pathology. In addition, future studies could be
targeted at understanding graft-versus-leukemia effects in
the setting of cGVHD, because human leukemia cell lines or
primary samples could be concurrently implanted. Finally,
the results presented here show there is a substantial
window of time after the transplanted human immune cells
have developed within the murine host in which there is
little or no xenopathology. Thus, the knowledge that GVHD
develops in HSC-L-T mice only after a substantial time delay
will further facilitate the use of this model for studying
immune responses by human cells in the context of many
other diseases, including infection by human-speciﬁc path-
ogens such as HIV and EBV.ACKNOWLEDGMENTS
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